Published • loading... • Updated
Pharma Task Force Urges Health Canada to Streamline Regulatory Reviews as Part of Suite of Recommendations
The report says Canada’s 2-year drug approval and pricing delays are pushing companies to favor faster markets and investment destinations.
Summary by The Globe & Mail
2 Articles
2 Articles
Feds' pharma task force says cutting time to get medicines onto public plans should be a priority with a three-month deadline
The federally appointed group’s report released on July 24 says the multi-year process between Health Canada’s approval and drug pricing negotiations is contributing to companies ‘deprioritizing Canada for product launches.’
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
